单次筛查检出心房颤动的估计卒中风险、检出率及需筛查人数:141220名受筛者的多国患者水平Meta分析
该研究通过系统检索和患者水平Meta分析,纳入19项研究、14个国家、141220名受筛者,发现筛查检出心房颤动的检出率随年龄增长而升高,≥65岁人群的年龄/性别调整检出率为1.44%,≥65岁人群的需筛查治疗人数为83;≥75岁新发心房颤动均符合1类口服抗凝推荐。
要点
- ≥65岁人群筛查检出心房颤动的年龄/性别调整检出率为1.44%(95%CI 1.13%-1.82%)。
- ≥65岁人群需筛查治疗人数为83,60-64岁为926,<60岁为1089。
- ≥75岁新发心房颤动均符合1类口服抗凝治疗推荐,65-74岁中66%符合。
核心结论
- 筛查检出心房颤动者计算卒中风险升高:65岁以上多数符合1类口服抗凝推荐,且>70%有年龄/性别以外的至少1项卒中危险因素。
- 检出率与估计卒中风险随年龄的精确关系,以及需筛查治疗人数对人群年龄分布的强依赖性,为精确的成本效果计算提供必要信息。
研究设计与样本
- 系统检索Medline、Pubmed和Embase(2007年1月至2018年2月),并联系AF-SCREEN国际合作成员识别额外研究。
- 纳入24项在≥65岁普通门诊人群中行单次心房颤动筛查的合格研究,邀请作者共享患者水平数据,最终19项研究(14个国家,低-中-高收入国家混合)合作,共141220名受筛者、1539例新发心房颤动。
- 采用随机效应逻辑回归分析心房颤动检出率,采用泊松回归模型分析CHA2DS2-VASc评分。
主要发现
- 筛查汇总检出率在所有年龄层中男性均高于女性;≥65岁人群年龄/性别调整检出率为1.44%(95%CI 1.13%-1.82%),<65岁为0.41%(95%CI 0.31%-0.53%)。
- 新发心房颤动检出率随年龄逐渐升高,从<60岁的0.34%升至≥85岁的2.73%。
- 筛查方法或设备选择、地理区域、筛查场所均未影响心房颤动检出率。
- 平均CHA2DS2-VASc评分(n=1369)随年龄从<60岁的1.1升至≥85岁的3.9;≥65岁人群中72%有年龄/性别以外的至少1项额外卒中危险因素。
- 所有≥75岁新发心房颤动及65-74岁中66%符合1类口服抗凝推荐;需筛查治疗人数≥65岁为83,60-64岁为926,<60岁为1089。
关键数值与推荐
- ≥65岁人群筛查检出心房颤动的年龄/性别调整检出率为1.44%(95%CI 1.13%-1.82%)。
- 需筛查治疗人数:≥65岁为83,60-64岁为926,<60岁为1089。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性为缺乏足够关于人群社会人口学变量的数据以及可能的确认偏倚,以解释样本间的方差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The precise age distribution and calculated stroke risk of screen-detected atrial fibrillation (AF) is not known. Therefore, it is not possible to determine the number needed to screen (NNS) to identify one treatable new AF case (NNS-Rx) (i.e., Class-1 oral anticoagulation [OAC] treatment recommendation) in each age stratum. If the NNS-Rx is known for each age stratum, precise cost-effectiveness and sensitivity simulations can be performed based on the age distribution of the population/region to be screened. Such calculations are required by national authorities and organisations responsible for health system budgets to determine the best age cutoffs for screening programs and decide whether programs of screening should be funded. Therefore, we aimed to determine the exact yield and calculated stroke-risk profile of screen-detected AF and NNS-Rx in 5-year age strata. METHODS AND FINDINGS: A systematic review of Medline, Pubmed, and Embase was performed (January 2007 to February 2018), and AF-SCREEN international collaboration members were contacted to identify additional studies. Twenty-four eligible studies were identified that performed a single time point screen for AF in a general ambulant population, including people ≥65 years. Authors from eligible studies were invited to collaborate and share patient-level data. Statistical analysis was performed using random effects logistic regression for AF detection rate, and Poisson regression modelling for CHA2DS2-VASc scores. Nineteen studies (14 countries from a mix of low- to middle- and high-income countries) collaborated, with 141,220 participants screened and 1,539 new AF cases. Pooled yield of screening was greater in males across all age strata. The age/sex-adjusted detection rate for screen-detected AF in ≥65-year-olds was 1.44% (95% CI, 1.13%-1.82%) and 0.41% (95% CI, 0.31%-0.53%) for <65-year-olds. New AF detection rate increased progressively with age from 0.34% (<60 years) to 2.73% (≥85 years). Neither the choice of screening methodology or device, the geographical region, nor the screening setting influenced the detection rate of AF. Mean CHA2DS2-VASc scores (n = 1,369) increased with age from 1.1 (<60 years) to 3.9 (≥85 years); 72% of ≥65 years had ≥1 additional stroke risk factor other than age/sex. All new AF ≥75 years and 66% between 65 and 74 years had a Class-1 OAC recommendation. The NNS-Rx is 83 for ≥65 years, 926 for 60-64 years; and 1,089 for <60 years. The main limitation of this study is there are insufficient data on sociodemographic variables of the populations and possible ascertainment biases to explain the variance in the samples. CONCLUSIONS: People with screen-detected AF are at elevated calculated stroke risk: above age 65, the majority have a Class-1 OAC recommendation for stroke prevention, and >70% have ≥1 additional stroke risk factor other than age/sex. Our data, based on the largest number of screen-detected AF collected to date, show the precise relationship between yield and estimated stroke risk profile with age, and strong dependence for NNS-RX on the age distribution of the population to be screened: essential information for precise cost-effectiveness calculations.
引用
- Lowres N, Olivier J, Chao TF, et al. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. PLoS Med. 2019. PMID: 31553733. doi:10.1371/journal.pmed.1002903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。